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Highly proliferating cells, such as cancer cells, have an elevated metabolic demand for protein synthesis1. The vast majority of proteins is produced in the cytosol and depends on the 
correct assembly of ribosomes. Ribosome biogenesis requires the 
activity of all three nuclear RNA polymerases2. Whereas the bio-
genesis of ribosomal proteins is initiated in the nucleus by the RNA 
polymerase II, maturation of a polycistronic precursor generated by 
RNA pol I in the nucleolus, gives rise to 18S, 28S and 5.8S rRNAs 
that are subsequently modified and processed by hundreds of small 
nucleolar RNAs (snoRNAs) and protein cofactors into their mature 
forms. The 5S rRNA instead, is transcribed independently in the 
nucleoplasm by the RNA pol III3.
The synthesis of 13 of the mitochondrial membrane proteins 
engages a dedicated set of ribosomes, or mitoribosomes, whose 
biogenesis requires active transcription by the mitochondrial poly-
merase to produce the mitochondrial rRNAs precursor that is then 
cleaved by RNase H and p32 to produce the mature 12S and 16S4. 
(Mito)ribosome biogenesis is the most energy-consuming cellular 
process3 and it is therefore tightly regulated by growth and stress 
signaling pathways5–8.
Apart from the aforementioned 13 membrane peptides, the 
majority of the mitochondrial proteome is encoded by the nuclear 
genome and synthesized in the cytosol as precursor proteins that 
are ultimately imported into mitochondria9. Thus, a fully functional 
oxidative phosphorylation chain requires proteins translated by 
both mitochondrial and cellular machineries. The two translation 
apparatuses therefore need to be synchronized and tightly regu-
lated to respond to environmental cues in a coordinated fashion. 
Accordingly, desynchronization through disruptions of mitochon-
drial protein synthesis impacts cell proliferation and fitness10–12, 
thus highlighting the existence of intracellular circuit(s) that couple 
mitochondrial translation to cell proliferation13. In yeast, mito-
chondrial protein synthesis defects cause mitochondrial membrane 
depolarization thus impairing the import of nuclear-encoded mito-
chondrial precursors. These accumulate in the cytosol to induce 
a proteotoxic stress response, known as mitochondrial precursor 
overaccumulation stress (mPOS)14,15.
Similarly to mitochondrial translation, cytosolic protein synthe-
sis is tightly linked to cell proliferation and under direct control of 
oncogenes and tumor suppressors16. Increasing evidence indicates 
that oncogenes can stimulate the translation rates in the cytosol and 
mitochondria. However, how cancer cells ensure that the proper 
balance between the output of the two protein synthesis machiner-
ies is maintained remains unclear.
One example of an oncogene with a direct role in control of 
translation is the transcription factor Myc, which directly increases 
protein synthesis rates in the cytosol by controlling the expression 
of multiple components of the protein synthetic machinery17. Myc is 
also capable of enhancing the activity of the mitochondrial protein 
synthesis machinery. p32, a mitochondrial protein required for the 
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maturation of mitochondrial rRNAs, is a direct transcriptional tar-
get of Myc18. Attenuation of p32 expression reduces growth rate of 
glioma cells expressing Myc and impairs tumor formation in vivo18. 
Several mitochondrial ribosomal proteins were also identified as 
Myc targets and, among them, Ptcd3 (pentatricopeptide repeat 
domain 3) was shown to have a critical role in the maintenance of 
B-cell lymphomas12. This data raises the possibility that key onco-
genes can directly contribute to the maintenance of the necessary 
synchronization of the two protein synthesis machineries.
We recently described SAMMSON, a lineage-specific lncRNA 
aberrantly expressed in a large fraction (> 90%) of cutaneous mel-
anoma. Strikingly, melanoma cells are addicted to SAMMSON, 
irrespective of their genetic make-up or transcriptional state and 
they quickly undergo apoptosis on its inhibition19. We showed that 
SAMMSON interacts with p32 and promotes its efficient targeting 
to mitochondria19. Accordingly, SAMMSON depletion caused mito-
chondrial protein synthesis defects resulting in membrane depo-
larization and activation of a mPOS-like response19. It therefore 
remains unclear whether SAMMSON itself is capable of—concomi-
tantly—provoking an adaptive cytosolic response to ensure a coor-
dinated increase of the cytosolic and mitochondrial translation rates 
or whether this is driven by SAMMSON-independent mechanisms.
To address this we searched for new SAMMSON-interacting 
proteins and identified XRN2 (5′ -3′ Exoribonuclease 2) and CARF 
(collaborator of ARF, the product of the CDKN2AIP gene), two 
proteins known to play key roles in the biogenesis of cellular ribo-
somes. XRN2 is a 5′ -3′ exoribonuclease with a crucial role in the 
maturation of virtually all RNA species and in nuclear RNA turn-
over. In the nucleoplasm, XRN2 participates in 3′ -end processing of 
mRNA20 and in the degradation of several transfer RNAs (tRNAs) 
including the initiator tRNA(Met) in stress conditions21,22. In the 
nucleoli, XRN2 is essential for the processing of snoRNA ends2,23,24 
and for the degradation of spacer fragments that are excised during 
rRNA maturation, thus ensuring proper maturation of the 5.8S and 
28S rRNAs2,25.
XRN2 access to the nucleoli is dynamically regulated by CARF, 
which titrates XRN2 excess by retaining it in the nucleoplasm to 
fine-tune pre-rRNA maturation26. Accordingly, CARF overexpres-
sion impairs rRNA processing26.
Here we show that SAMMSON promotes CARF binding to 
p32 thus interfering with its binding to XRN2. This favors XRN2 
localization to the nucleoli and p32 targeting to mitochondria and 
thereby the stimulation of rRNA biogenesis and protein synthesis in 
both compartments. By boosting translation, SAMMSON confers a 
growth advantage to immortalized cells irrespective of their tissue 
of origin.
Results
SAMMSON increases the tumorigenic potential in a lineage-
independent fashion. We established that melanoma cells are 
addicted to SAMMSON independently of their genetic make-up19. 
As SAMMSON’s expression becomes readily detectable at the early 
stages of melanomagenesis19, we asked whether a causative link exists 
between its expression and malignant transformation. We tested the 
effects of ectopic SAMMSON expression on immortalized Mel-ST 
cells belonging to the melanocytic lineage27 (Supplementary Fig. 1). 
Ectopic expression of SAMMSON under the control of a phospho-
glycerate kinase promoter using a lentiviral-based approach, con-
ferred growth advantage in vitro (Supplementary Fig. 1a–d) and 
allowed tumor growth in nude mice, indicating that its presence 
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Fig. 1 | SAMMSON induces a malignant phenotype outside of the melanocytic lineage. a, SAMMSON expression measured by RT–qPCR in LCL cells 
infected with an empty (Ctrl) or a SAMMSON-encoding (SAM O/E) expression vector and/or with SV40 LTA; n =  6 independent experiments. SAM O/E 
values are relative to the Ctrl sample and SAM O/E +  LTA values are relative to the Ctrl +  LTA sample. b, Cell proliferation assays in LCL cells described 
in a. Error bars represent mean ±  s.e.m.; n =  4 independent experiments. c, Soft agar assay in LCL cells described in a. Representative images of three 
independent experiments. d, Quantification of number of colonies formed in soft agar as described in c. Error bars represent mean ±  s.e.m.; n =  3 
independent experiments. e, Quantification of colony size of soft agar colonies as described in c. Error bars represent mean ±  s.e.m.; n =  3 independent 
experiments. P values were calculated by paired two-tailed Student’s t-test. *P <  0.05; **P <  0.01; ****P <  0.0001. A.U.; arbitrary unit. Source data for panels 
a, b, d and e are available in the Supplementary Information.
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is sufficient to transform immortalized cells of melanocytic origin 
(Supplementary Fig. 1e–g).
SAMMSON also conferred a growth advantage to cells that do 
not belong to the melanocytic lineage, namely the immortalized 
lymphoblastoid cell line (LCL; SAMMSON-negative) (Fig. 1a,b). 
Ectopic SAMMSON expression in these cells cooperated with the 
large T antigen (LTA) in promoting transformation (Fig. 1c–e). The 
combined expression of SAMMSON and LTA led to an increase in 
growth that significantly exceeded that of the LTA alone (Fig. 1b). 
Moreover, while control LCLs were unable to grow in soft agar, 
LCLs expressing both SAMMSON and LTA were capable of form-
ing more and larger colonies than LCL cells expressing LTA alone 
(Fig. 1c–e). These findings demonstrated the ability of SAMMSON 
to enhance malignant transformation within and outside the mela-
nocytic lineage.
Desynchronization of cytosolic and mitochondrial transla-
tion machinery is detrimental and can be exploited therapeu-
tically. We established that knockdown of SAMMSON decreases 
melanoma viability by impairing mitochondrial translation and 
inducing an mPOS-like response19. This finding suggested that 
disruption of the equilibrium between cytosolic and mitochondrial 
protein synthesis impairs melanoma cell fitness13. Accordingly, 
acute depletion of SAMMSON using antisense oligonucleotides19 
in the established melanoma line SK-MEL-28 (Fig. 2a) caused 
severe defects in mitochondrial protein synthesis (Fig. 2b,c) and 
apoptotic responses19 before any impact on cytosolic protein syn-
thesis could be observed (Fig. 2b,c). Both antisense oligonucle-
otides (Gapmer3 and 11) have previously been selected for their 
ability to efficiently decrease SAMMSON expression without caus-
ing any off-target effects19.
Loss of cell viability induced by SAMMSON knockdown was 
phenocopied by specific inhibition of mitochondria protein syn-
thesis using chloramphenicol (Fig. 2d,e). Designed to target bacte-
rial ribosomes, chloramphenicol and antibiotics of the tetracyclines 
family are also effective in inhibiting the structurally related mitori-
bosomes11,12. Consequently, survival of SK-MEL-28 melanoma cells 
exposed to chloramphenicol was compromised in a dose-depen-
dent manner (Fig. 2d,e). This data identified the balance between 
cytosolic and mitochondrial protein synthesis rates as an exploitable 
therapeutic vulnerability in melanoma. Accordingly, an antibiotic 
in clinical use such as Tigecycline sensitized ‘invasive’ (therapy 
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Fig. 2 | Desynchronization of cytosolic and mitochondrial translation machinery decreases melanoma cell fitness and can be therefore exploited 
therapeutically. a, SAMMSON expression measured by RT–qPCR in SK-MEL-28 cells transfected with a non-targeting GapmeR(Ctrl) or GapmeR3. Error 
bars represent mean ±  s.e.m.; n =  3 independent experiments. Values are relative to the non-targeting GapmeR (Ctrl) sample. b, Western blotting after 
a 10-min pulse with puromycin and subsequent cytosol (Cyto)-mitochondria (Mito)-mitoplast (Mitopl) fractionation in SK-MEL-28 cells described in 
a. Representative images of three independent experiments. c, Quantification of protein synthesis (%), measured by calculating the intensity of the 
puromycin signal on western blot, in SK-MEL-28 cells as described in a and b. Error bars represent mean ±  s.e.m.; n =  3 independent experiments. Values of 
each cellular fraction are relative to the non-targeting GapmeR (Ctrl) sample. d, Colony formation assays 5 days after seeding 1 ×  103 SK-MEL-28 cells and 
treating them with increasing amounts of chloramphenicol or vehicle (EtOH). The violet color is due to crystal violet, a compound that binds intracellular 
DNA and protein, thus highlighting the cells attached to the plate. Representative image of three independent experiments. e, Caspase 3/7 activity 72 h 
after treating SK-MEL-28 cells with increasing amounts of chloramphenicol or vehicle (EtOH). Error bars represent mean ±  s.e.m.; n =  3 independent 
experiments. P values were calculated with two-way ANOVA comparing the two treatments (chloramphenicol versus vehicle). f, Cell viability of MM099 
cells measured 48 h after treatment with either Tigecycline or a combination of Tigecycline, BRAFi (Dabrafenib) and MEKi (Trametinib). Error bars 
represent mean ±  s.e.m.; n =  3 independent experiments. P values were calculated by paired two-tailed Student’s t-test. Values are relative to the non-
treated sample (first bar on the left). *P <  0.05; **P <  0.01; ***P <  0.001; NS, not significant. Uncropped gel images are shown in Supplementary Data Set 1. 
Source data for panels a, c, e and f are available in the Supplementary Information.
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Fig. 3 | SAMMSON interacts with XRN2 and CARF. a, SAMMSON (but not TBP or UBC) is specifically recovered by RNA antisense purification (RAP) after 
ultraviolet crosslinking SK-MEL-28 cells as measured by RT–qPCR. Enrichments were calculated by normalizing the RAP over the inputs using the ∆ ∆ Ct 
method (see Methods). Genes not detectable in the RAP were assigned a value of 0. Representative graph of three independent experiments. b, SAMMSON 
and HRPT pulldown in native conditions (using two sets of 48 biotinylated probes recognizing mature transcripts, p) and western blotting with anti-XRN2, 
anti-CARF and anti-SRSF1 antibodies in SK-MEL-28 cells. Representative image of three independent experiments. c, SAMMSON and HRPT pulldown in  
native conditions (using biotinylated probes, p) and western blotting in mouse p38 cells with anti-XRN2, anti-CARF and anti-p32 antibodies. Representative 
image of three independent experiments. d, MALAT1 (but not SAMMSON or HPRT) is recovered by RNA immunoprecipitation (RIP) using an SRSF1-specific 
antibody as measured by RT–qPCR in SK-MEL-28 cells. Enrichments were calculated by normalizing the RIP over the inputs using the ∆ ∆ Ct method (see the 
Methods section). Genes not detectable in the RIP were assigned a value of 0. Error bars represent mean ±  s.e.m.; n =  3 independent experiments. e, Western 
blot with an anti-SRSF1 antibody following RIP with an anti-SRSF1 antibody in SK-MEL-28 cells. Representative image of three independent experiments.  
f, SAMMSON and TERRA are recovered by RIP using an XRN2-specific antibody as measured by RT–qPCR in SK-MEL-28 cells. Enrichments were calculated by 
normalizing the RIP over the inputs using the ∆ ∆ Ct method (see Methods). Genes not detectable in the RIP were assigned a value of 0. Error bars represent 
mean ±  s.e.m.; n =  3 independent experiments. g, Western blot with anti-XRN2 and anti-CARF antibodies following RIP with an anti-XRN2 antibody in  
SK-MEL-28 cells. Representative image of three independent experiments. h, SAMMSON and LINC00698 are recovered by RIP using a CARF-specific antibody 
as measured by RT–qPCR in SK-MEL-28 cells. Enrichments were calculated by normalizing the RIP over the inputs using the ∆ ∆ Ct method (see the Methods 
section). Genes not detectable in the RIP were assigned a value of 0. Error bars represent mean ±  s.e.m.; n =  3 independent experiments. i, Western blot with 
anti-XRN2 and anti-CARF antibodies following RIP with an anti-CARF antibody in SK-MEL-28 cells. Representative image of three independent experiments. 
Uncropped gel images are shown in Supplementary Data Set 1. Source data for panels a, d, f and h are available in the Supplementary Information.
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c and e are available in the Supplementary Information.
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Uncropped gel images are shown in Supplementary Data Set 1. Source data for panel c are available in the Supplementary Information.
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resistant)28 melanoma cells (MM099) to the combination of 
Dabrafenib and Trametinib (Fig. 2f).
This data demonstrated the importance of a coordinated transla-
tion in both compartments and indicated that disruption of mito-
chondrial translation is a valuable antimelanoma strategy.
SAMMSON interacts with CARF and XRN2, two proteins involved 
in ribosome biogenesis. Given that expression of SAMMSON is 
sufficient to promote malignant transformation and that cancer cell 
fitness depends on a synchronized increase in protein translation 
in the mitochondria and cytosol we hypothesized that SAMMSON 
may also control cytosolic translation. A search in our list of puta-
tive SAMMSON’s interacting partners19 identified XRN2 and CARF, 
two proteins implicated in ribosome biogenesis in the nucleus. 
Both proteins showed elevated expression in melanoma compared 
to normal human epidermal melanocytes (NHEM; Supplementary 
Fig. 2a). We confirmed the ability of SAMMSON to interact with 
these proteins using RNA pull-downs and RNA immunoprecipita-
tions (RIP). By specifically pulling-down SAMMSON using a pool of 
antisense oligonucleotides in native (Fig. 3a,b) and crosslinking con-
ditions (Supplementary Fig. 2b), we observed a robust enrichment 
for CARF and XRN2 (Fig. 3b and Supplementary Fig. 2b). In con-
trast, other abundant proteins such as vinculin or the RNA-binding 
protein SFRS1 could not be detected (Fig. 3b and Supplementary 
Fig. 2b). Additionally, no enrichment for these proteins was observed 
when performing the assay in the SAMMSON-negative mouse cell 
line p38 (Fig. 3c). Conversely, the lncRNA MALAT1 an established 
SFRS1-partner29, but not SAMMSON, was identified in SFRS1-
immunoprecipitates (Fig. 3d,e). Likewise, RNA fractions obtained 
from XRN2 and CARF immunoprecipitates (Fig. 3g,i) were enriched 
in SAMMSON, but not in the cytosolic RNAs TBP and HPRT  
(Fig. 3f–h). Further confirming the interaction, TERRA, a known 
XRN2 substrate30, was retrieved in XRN2, but not in CARF immu-
noprecipitates. In contrast, CARF, but not XRN2, associated specifi-
cally with another melanoma-specific lincRNA (LINC00698). This 
data validated CARF and XRN2 as bona fide SAMMSON interactors.
Consistent with previous findings, CARF and XRN2 co-immu-
noprecipitated (Fig. 3g,i) confirming their physical interaction21. 
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Source data for panels b–g are available in the Supplementary Information.
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This observation raised the possibility that SAMMSON may be 
engaged into a ribonucleoproteic complex containing both XRN2 
and CARF. Alternatively, SAMMSON may interact with both 
proteins independently, and even possibly modulate the XRN2-
CARF association. To address this, we mapped the XRN2-
SAMMSON’s interaction interface using three different HA-tagged 
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XRN2-deletion constructs26 (Fig. 4a). An interaction between 
SAMMSON and wild-type XRN2 was readily detected by RIP assays 
(Fig. 4b,c). Although SAMMSON did interact with the N1 form of 
XRN2, which lacks the last 270 amino acids, further deletion of 
another 171 amino acids containing an evolutionarily conserved 
region (mutant N2), abrogated the binding. Interestingly, this con-
served domain was also required for the interaction between XRN2 
and CARF (Fig. 4b,c)28.
Similarly to CARF, SAMMSON was also incapable of binding a 
XRN2 mutant lacking the first 152 amino acids (mutant C), which 
constitutes a large part of the catalytic domain. In contrast, the 18S 
ncRNA, known to be a XRN2 substrate25, required an intact car-
boxy-terminal half of the protein for binding, and did not occupy 
the catalytic domain (Fig. 4c). These observations could indicate 
that SAMMSON may modulate XRN2 functions rather than being 
a direct XRN2 substrate. In keeping with this, silencing XRN2 
stabilized TERRA, a known XRN2 substrate, but did not affect 
SAMMSON levels (Fig. 4d,e).
To identify which portion of SAMMSON is responsible for bind-
ing to XRN2, CARF and p32, we predicted their interactions ab 
initio using catRAPID31. catRAPID predicted an interaction inter-
face with all three proteins located in a region comprising the last 
400–300 nucleotides of SAMMSON (Fig. 4f). Based on these find-
ings, we designed two SAMMSON deletion mutants, in which we 
also inserted a RAT (RNA affinity in tandem)-tag (Fig. 4g). The 
aptamer recognizing the RAT-tag was FLAG-conjugated thus 
allowing us to purify SAMMSON-containing complexes with an 
anti-FLAG antibody. The experiment (Fig. 4h) confirmed the in 
silico predictions, since deletion of the last 500 nucleotides of the 
SAMMSON sequence impaired its ability to interact with XRN2, 
CARF and p32 (Fig. 4i). These data indicated that the 3’-end of 
SAMMSON engages in multiple protein interactions.
SAMMSON modulates XRN2 localization and nucleolar func-
tions. CARF regulates XRN2 access to the nucleoli (and related 
functions) by tethering it into the nucleoplasm26. To further inves-
tigate the relationship between XRN2, CARF and SAMMSON, we 
determined the localization of CARF and XRN2 on SAMMSON 
knockdown. Immunofluorescent staining revealed that SAMMSON 
silencing led to the complete exclusion of XRN2 from the nucleoli 
(Fig. 5a) and relocation of the cytoplasmic fraction of CARF to the 
nucleoplasm (Supplementary Fig. 3a).
To rule out the possibility that the nucleoplasmic relocation of 
XRN2 was an indirect consequence of the mitochondrial stress 
triggered by SAMMSON knockdown19, we interfered with mito-
chondrial translation via a distinct mechanism32 by treating the 
cells with chloramphenicol and determined XRN2 localization 
(Supplementary Fig. 3b,c). This confirmed that XRN2 localiza-
tion was not affected by this treatment (Supplementary Fig. 3b,c). 
Moreover, XRN2 localization was also unaffected by the silencing 
of NEAT1, another lncRNA reported to interact with XRN233 and 
implicated in stress responses34 (Supplementary Fig. 3d,e). Hence, 
the displacement of XRN2 from the nucleoli is a direct consequence 
of SAMMSON’s silencing.
XRN2 modulates the biogenesis of the cytosolic ribosome by 
processing the rRNA and snoRNA in the nucleolus. Displacement 
of XRN2 away from the nucleoli in SAMMSON-depleted cells indi-
cated that SAMMSON is likely to modulate XRN2 nucleolar func-
tions. Similar to XRN2 knockdown, SAMMSON knockdown caused 
the accumulation of an aberrant precursor, the 34S pre-rRNA, which 
arises from the inhibition in the cleavage of the 5’-ETS (external 
transcribed spacer; Fig. 5b and Supplementary Fig. 4a). Processing 
in the 5’-ETS and turnover of the cleaved fragments are intimately 
connected35. Accordingly, inhibition of the cleavage increased the 
amount of the fragment + 1-01 (Fig. 5b and Supplementary Fig. 4a). 
As a consequence, we observed an imbalanced production of 18S 
(Fig. 5c and Supplementary Fig. 4b). Moreover, consistent with 
previous data showing impaired mitochondrial targeting of p32 
and defective mitochondrial rRNA processing19, levels of mito-
chondrial rRNAs (12S and 16S) were also decreased (Fig. 5c and 
Supplementary Fig. 4b) while the expression of mitochondrial rRNA 
precursors slightly increased as a result of the defective processing 
(Supplementary Fig. 4c). Conversely, other mitochondrial tran-
scripts remained unaffected (Fig. 5c and Supplementary Fig. 4b).
Nucleolar XRN2 is also implicated in the maturation of the 
5’-ends of snoRNAs2,23,24. SnoRNAs are largely encoded in host gene 
introns and produced by endo- and exoribonucleolytic digestion of 
spliced-lariats36,37. Consistently, we detected aberrant 5’ extended 
forms of snoRNA precursors on SAMMSON silencing (Fig. 5d). 
Note that the processing of the 3’-end of snoRNA precursors was 
also affected. This may indicate that XRN2-mediated 5’-end pro-
cessing is required for subsequent trimming of the 3’-end.
In addition to its nucleolar functions XRN2 also exhibits a 
nucleoplasmic function linked to translation, such as the process-
ing and degradation of initiator tRNAMet21. Consistent with the 
complete re-localization of XRN2 into the nucleoplasm, a decreased 
expression of the initiator tRNA for methionine (tRNA61-MetCAT) 
was observed on SAMMSON depletion (Supplementary Fig. 4d). 
This data indicated that SAMMSON favors XRN2 localization to 
nucleoli and promotes its ability to support ribosome biogenesis.
SAMMSON rewires the melanoma RNA-binding protein net-
work involved in ribosome biogenesis. XRN2 exclusion from the 
nucleoli and its increased co-localization with CARF in the nucleo-
plasm on SAMMSON knockdown indicated that SAMMSON may 
interfere with CARF binding to XRN2. However, while SAMMSON 
is predominantly cytoplasmic19, XRN2 is exclusively nuclear. CARF 
instead, has been detected in both the nucleoplasm, where the 
interaction with XRN2 takes place26, and the cytoplasm, where 
its function remains unclear (Fig. 6a). Consistently, a pool of 
CARF was detected in the cytoplasm of melanoma cells (Fig. 6a). 
Immunostaining for CARF and p32, another validated SAMMSON’s 
interacting partner19, indicated that the two proteins co-localized in 
the cytoplasm of melanoma cells and their co-localization was lost 
on silencing of SAMMSON, when CARF relocated to the nucleus 
(Fig. 6a). Consistent with our findings showing that SAMMSON 
promotes mitochondrial targeting of p3219, SAMMSON’s depletion 
also affected the localization of p32 that diffusely localized to the 
cytoplasm and partly to the nucleus in SAMMSON knockdown cells 
(Supplementary Fig. 5a).
We then investigated the possibility that SAMMSON, CARF and 
p32 are engaged into a ribonucleoprotein complex. We performed 
RIP using melanoma cell extracts supplemented with RNase A 
(Fig. 6b). While p32 was readily detectable in CARF immunopre-
cipitates in absence of RNase A treatment, this interaction was 
abrogated in the presence of RNase A (Fig. 6b). Similar results were 
obtained with proximity ligation assay (PLA) for CARF and p32 
(Supplementary Fig. 5b). Conversely, similar RIP experiments in 
LCLs, which do not express SAMMSON, failed to detect an associa-
tion between CARF and p32 (Fig. 6c and Supplementary Fig. 5c). 
This data indicated that p32 and CARF interact specifically in mela-
noma cells and in an RNA-dependent manner. To test whether this 
interaction is mediated by SAMMSON itself, we used LCLs and 
assessed binding between CARF and p32 using RIP assays (Fig. 6c  
and Supplementary Fig. 5c, respectively). Ectopic expression of 
SAMMSON alone was sufficient to trigger the binding between CARF 
and p32 and promoted export of a fraction of CARF to the cytoplasm 
(Supplementary Fig. 5d). Accordingly, knockdown of CARF affected 
the mitochondrial network architecture (Supplementary Fig. 6a).
Moreover, PLA in Mel-ST expressing SAMMSON ectopically 
further confirmed that the interaction is SAMMSON-dependent 
(Supplementary Fig. 6b).
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Conversely, RIP for CARF showed increased binding of XRN2 
to CARF in SAMMSON knockdown cells and this occurred at the 
expense of CARF-p32 interaction (Fig. 6d,e and Supplementary 
Fig. 6c,d). PLA further confirmed that SAMMSON silencing 
decreases the number of interactions between CARF and p32 
(Fig. 6f–h).
These findings established that SAMMSON’s expression is suf-
ficient to trigger an ‘aberrant’ interaction between CARF and p32 to 
promote CARF re-localization to the cytoplasm. Remarkably, ecto-
pic expression of SAMMSON was sufficient to drive this interaction 
even in cells that are not derived from the melanocytic lineage.
SAMMSON promotes translation in both the cytosol and mito-
chondria. This data indicated that SAMMSON may stimulate ribo-
some biogenesis to concertedly increase mitochondrial and cytosolic 
translation. Consistently, ectopic expression of SAMMSON in the 
immortalized human Mel-ST cells resulted in an increased amount 
of nuclear rRNA (Fig. 7a and Supplementary Fig. 7a). SAMMSON 
expression also resulted in global increase in de novo translation 
rates in both cytosolic and mitochondrial compartments, as illus-
trated by puromycin incorporation assay (SUnSET38) (Fig. 7b and 
Supplementary Fig. 7b). Importantly, the increase in translation was 
detectable 30 h after transfection, before any significant impact on 
cell proliferation could be measured (48 h time point; Fig. 1b and 
Supplementary Fig. 1b). This observation rules out the possibility 
that the increase in translation rate is a consequence of increased 
cell proliferation. Increased translation was also detected in Mel-ST 
xenografts (Fig. 7g and Supplementary Fig. 7f,g). Similar results 
were obtained in the LCLs transduced with SAMMSON and the 
LTA (Fig. 1). Overexpression of SAMMSON, but not LTA alone, 
induced a robust increase in translation in both compartments 
(Fig. 7c and Supplementary Fig. 7c). This result was further con-
firmed by metabolic labeling with l-azidohomoalanine followed by 
extraction of mitochondria in proteinase K on SAMMSON over-
expression, thus indicating that the increased signal was unlikely 
to derive from cytosolic ribosomes attached to the mitochondrial 
membrane (Supplementary Fig. 7e). Consistent with previous 
results19, we could not detect any change in p32 mRNA expres-
sion (Fig. 7d), however, its protein levels in the mitochondria were 
significantly increased (Fig. 7e,f and Supplementary Fig. 7c,d). We 
concluded that SAMMSON is capable of stimulating ribosome bio-
genesis, and thereby protein synthesis, by rewiring complex forma-
tion and cellular localization of proteins involved in the maturation 
of nuclear and mitochondrial rRNA.
Discussion
Nucleolar hypertrophy has long been recognized as a hallmark of 
cancer39 and changes in nucleolar functions contributes to malig-
nant transformation. Accordingly, several RNA polymerase I inhib-
itors have been introduced in the clinic and/or enrolled into clinical 
trials40,41. A growing body of evidence indicates that quantitative and 
qualitative reprogramming of cytosolic and mitochondrial transla-
tion are required to sustain tumor development and progression42. 
Moreover, cytosolic and mitochondrial protein synthesis machiner-
ies need to be balanced to avoid proteotoxic stress14,43,44. While mito-
chondria are relatively efficient at adjusting their protein synthesis 
rate to the income in cytosolic proteins44, deregulation of mitochon-
drial translation invariably induces detrimental responses19,45, prob-
ably due to the higher stability of cytosolic ribosomes and to the 
multiple regulatory steps downstream of ribosome biogenesis. Our 
data suggests that disruption of this equilibrium by blocking mito-
chondrial translation, either by knocking down lineage-specific 
lncRNAs, such as SAMMSON or treatment with antibiotics, can be 
exploited therapeutically to kill cancer cells.
We previously showed that melanoma cells are addicted to 
SAMMSON, a lncRNA interacting with p32 to regulate mitochondrial 
protein synthesis19. Here, we establish SAMMSON as a key player in 
nuclear-mitochondrial communication and a guardian of proteos-
tasis in melanoma. It stimulates rRNA maturation in the nucleoli 
and increases the rate of cytosolic protein synthesis (Fig. 8).
SAMMSON participates in the reprogramming of the nucleolar 
activities in this context by modulating the subcellular localization 
of XRN2 (Fig. 8). Through this process, SAMMSON stimulates 
rRNA and snoRNA processing in the nucleoli, stabilizes tRNAMet in 
the nucleoplasm and, ultimately, increases translation in the cytosol, 
thus increasing cancer cell fitness.
The ability of SAMMSON to perturb the formation of a com-
plex between CARF and XRN2 was unexpected considering that the 
CARF-XRN2 interaction was reported to be RNA-independent26.
Our data indicates that SAMMSON may interfere with the 
formation of the CARF-XRN2 complex via distinct mechanisms 
and the relative contributions of these mechanisms remains to be 
established.
Since both SAMMSON and CARF bind to overlapping domains 
of XRN2, SAMMSON may either mask the CARF binding site or 
promote (or impair) the deposition of post-translational modifica-
tions that affects XRN2 localization and (or) function. In addition, 
in presence of SAMMSON, CARF switches from a nuclear complex 
with XRN2 to an aberrant complex with p32 into the cytoplasm. 
CARF cytoplasmic re-localization physically limits its ability to 
interact with XRN2, which is exclusively nuclear. XRN2 exerts 
specific functions in different sub-nuclear compartments and its 
biological activities are therefore strongly dependent on compart-
mentalization rather than specificity in the selection of its substrates.
Overall, the rewiring of the RNA-binding protein network 
increases concomitantly cytosolic and mitochondrial protein syn-
thesis rates (Fig. 8). This switching mechanism probably provides 
cancer cells with a growth advantage and may therefore be exploited 
by other oncogenic noncoding RNAs and/or proteins. It will there-
fore be interesting to assess whether similar mechanisms are at play 
in other types of cancer.
Although it remains to be formally established that its expres-
sion is cancer-specific, it is tempting to speculate that SAMMSON is 
expressed exclusively in melanoma cells as a by-product of aberrant 
RNA biology. A similar example is provided by a protein-coding 
gene ∆ N-Netrin-1, a variant of Netrin-1 produced by transcription 
from an internal promoter and detectable only in cancer cells46. In 
contrast with the Netrin-1 protein, which is secreted, the cancer 
variant localizes aberrantly to the nucleoli where it affects rRNA 
processing and nucleolar structure46. Here we show that SAMMSON 
aberrant expression is sufficient to impose CARF binding to p32, 
stimulate cytosolic and mitochondrial translation and enhance 
malignancy in a lineage-independent manner. SAMMSON could 
therefore be viewed as a selfish gene, which tries to perpetuate its 
expression by increasing proliferation of malignant cells through 
increased translation.
Together we showed that the oncogenic lncRNA SAMMSON 
hijacks key RNA-binding proteins to concertedly enhance transla-
tion in the cytosol and in the mitochondria. This ensures the main-
tenance of the equilibrium between the two translation rates, which 
is so essential for cancer cell survival. Targeting this equilibrium 
through inhibition of mitochondrial protein synthesis machinery is 
emerging as a promising antimelanoma strategy.
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Methods
Cell culture and transfection. All lines were grown in 5% CO2 at 37 °C.  
SK-MEL-28 (a gift from L. Larue), SK-MEL-28 BRAFi resistant (a gift from  
D. Peeper) and LCLs (a gift from L. Leoncini) were grown in RPMI 1640-glutamax 
(Gibco, Invitrogen) supplemented with 10% FBS (Gibco, Invitrogen). Mel-ST 
(a gift from C. Bertolotto) were grown in DMEM-glutamax (Gibco, Invitrogen) 
supplemented with 7% FBS (Gibco, Invitrogen). HEK293T (from ATCC) were 
grown in DMEM-glutamax (Gibco, Invitrogen) supplemented with 10% FBS 
(Gibco, Invitrogen). The patient-derived passages multiple myeloma cell line (a gift 
from G.-E. Ghanem) were grown in F-10 (Gibco, Invitrogen), supplemented with 
10% FBS (Gibco, Invitrogen) and 12 mM Glutamax (Gibco, Invitrogen). NHEM  
(a gift from H. Brems) were grown in MGM-4 melanocyte growth medium 
(Lonza). p38 cells were grown in F-12 media (Gibco, Invitrogen) supplemented 
with 10% FBS (Gibco, Invitrogen), 2 mM Glutamine (Gibco, Invitrogen) and  
25 µ g ml−1 of Hygromycin B (Thermo Fisher Scientific). All cell lines used in this 
study were mycoplasma negative.
Cells were transfected with Lipofectamine 2000 (Thermo Fisher Scientific) 
according to manufacturer instructions with 25 nM of non-targeting GapmeR 
or SAMMSON-targeting GapmeR3 or 11 (Exiqon) and collected 30 h after 
transfection, with 25 nM siCARF (SMART-pool, Dharmacom) or with 50 nM 
of siXRN2 (Sigma-Aldrich) and collected 72 h after transfection. Cells were 
transfected with Lipofectamine RNAiMax (Thermo Fisher Scientific) according 
to the manufacturer instructions with 25 nM of siNEAT1 siPOOLs (siTOOLS 
Biotech) and fixed 72 h after transfection. Sequences of the GapmeRs and  
siRNAs are indicated in Supplementary Table 1. For HA-XRN2 constructs 
transfection, four 15 cm ∅ plates per construct were transfected with 25 µ g  
plasmid per plate and 70 µ l Lipofectamine 2000 per plate and samples were 
collected 72 h after transfection. HEK293T cells were transfected with standard 
calcium phosphate method.
Cloning and lentiviral transduction. The SAMMSON-encoding construct was 
described elsewhere19. SAMMSON deletion constructs ± RAT-tag were generated 
as follows. SAMMSON complementary DNA fragment was amplified by a 
polymerase chain reaction (PCR) using primer sets HIW885 and HIW886 with 
the SAMMSON-encoding pLenti_PGK_SAMMSON plasmid as a template. The 
PCR product was ligated into BamH I-Xho I sites of pcDNA5-FRT-TO vector 
and the resulting product was used for transformation of DH5𝛼 competent cells 
to obtain single clones. Sub-cloned product pcDNA5-FRT-TO-SAMMSON was 
verified by DNA sequencing. For construction of the RNA aptamer fused with 
SAMMSON, RAT-tag was amplified by PCR using the primer sets HIW897 and 
HIW898 with the previously described47 RAT-U1 snRNA expression vector as 
template. Amplified RAT-tag coding fragment was ligated into Xho I-Apa I sites 
of pcDNA5-FRT-TO-SAMMSON. The resulting product (pcDNA5-FRT-TO-
SAMMSON_RAT-tag) was verified by DNA sequencing. Using pcDNA5-FRT-TO-
SAMMSON_RAT-tag as a template, SAMMSON deletion mutant coding fragments 
were amplified by PCR with the following primer sets: HIW885 and HIW899 for 
SAMMSON-5’ half, HIW900 and HIW886 for SAMMSON-3’ half, and HIW901 
and HIW886 for SAMMSON-3’ 500 base, respectively. After removing the full-
length SAMMSON sequence from pcDNA5-FRT-TO-SAMMSON_RAT-tag using 
BamH I-Xho I restriction enzymes, the PCR products were ligated into the same 
sites. Resultant deletion constructs were verified by DNA sequencing. All primer 
sequences are indicated in Supplementary Table 1.
HA-XRN2 constructs (WT, C, N1 and N2) were previously described in ref. 26. 
For SAMMSON infection, lentivirus produced in HEK293T cells was used to infect 
the Mel-ST and LCLs cells. Successfully infected cells were selected in a puromycin 
(InvivoGen, 0.5 μ g ml−1)-containing medium for 1 week. For SV40 LTA (a gift from 
A. Sablina) infection, lentivirus produced in HEK293T cells was used to infect  
LCL cells. Successfully infected cells were selected in a hygromycin B (Invitrogen, 
100 μ g ml−1)-containing medium for 1 week to 2 weeks.
Cell growth and cell death assays. Cell growth was measured with the 
CellTiter-Glo luminescent cell viability assay (Promega), Caspase activity was 
measured using the Caspase-Glo 3/7 assay (Promega) with a VIKTOR X4 
Reader (PerkinElmer). Tigecycline (Sellekem) was used at a 5, 25 or 50 μ M 
concentration. BRAFi (Dabrafenib-TAFINLAR, Novartis) and MEKi (Trametinib-
MEKINIST, Novartis) were used at 10 nM and 2.5 nM concentrations, respectively. 
Chloramphenicol (Sigma-Aldrich) was used at a 100, 200 or 400 μ g ml−1 
concentration.
Cell count, colony assays and soft agar assays. For vital counts, cells were  
stained with Trypan Blue (Sigma-Aldrich) and counted with TC20 automated cell 
counter (Biorad).
For colony assays, 1 × 103 Mel-ST or SK-MEL-28 cells were plated in six-well 
plates and cultured for 1 week. The cells were then fixed and stained for 15 min 
with a 1% crystal violet in 35% methanol solution. Chloramphenicol (Sigma-
Aldrich) was used at a 100–200–400 μ g ml−1 concentration.
For soft agar assay, 1 × 104 cells were embedded in 1 ml of RPMI 1640 
containing 10% FBS and 0.35% noble agar (Sigma-Aldrich) on a base layer made 
of RPMI 1640 containing 10% FBS and 2% noble agar in a well of a six-well plate. 
After 2–3 weeks of incubation, cells were fixed and stained with a crystal violet 
solution (0.05% crystal violet, 0.05% methanol and 0.37% PFA) for 2 h.
RAP-WB. For the validation of protein targets, two sets of 48 tiling probes were 
used to affinity purify mature SAMMSON and HPRT transcripts (Biosearch 
Technologies). Briefly, 100 μ l of Streptavidin Sepharose High Performance 
beads (GE Healthcare) were coupled to 400 pmol of biotinylated probes against 
SAMMSON overnight at 4 °C. Cells (6 × 107 cells per sample) were lysed in 2 ml 
of pull-out buffer (20 mM Tris-HCl pH 7.5, 200 mM NaCl, 2.5 mM MgCl2, 0.05% 
Igepal, 60 U ml−1 Superase-In (Ambion), 1 mM dithiothreitol (DTT) and 1× Halt 
Protease and Phosphatase Inhibitor Single-Use Cocktail (Life Technologies)) and 
incubated for 3 h with the beads at 4 °C on a rotating wheel. As a negative control, 
an additional sample was digested with 10 μ g ml−1 RNase A for 10 min at room 
temperature before incubation with SAMMSON probes.
For the crosslinking experiments, cells were washed once in phosphate  
buffer saline, crosslinked dry at 400 mJ cm−1 and lysed. Washes were performed in 
RNase-free water.
RIP. RIP was performed as previously described48. p32, XRN2 and CARF were 
immuno-precipitated using 4 μ g of specific antibody (p32, A302-862A, Bethyl 
Laboratories; XRN2, A301-103A, Bethyl Laboratories; CARF, A303-862A, Bethyl 
Laboratories) coupled to 35 μ l of protein G Dynabeads (Invitrogen) overnight at 
4 °C on a rotating wheel.
RIP/RAP efficiency. The relative expression of the genes of interest for the RIP/
RAP assays was calculated applying the ∆ ∆ Ct method. In brief, the Ct value of 
the RIP/RAP was subtracted from the Ct value of the Input for every gene, thus 
obtaining the ∆ Ct for each gene in the RIP/RAP sample. The RIP/RAP ∆ Ct was 
then subtracted from the ∆ Ct of the immunoglobin (IgG), control probe or control 
sample (WT for Fig. 4c) for every gene, thus obtaining the ∆ ∆ Ct. To calculate the 
fold enrichment, the following equation was applied: fold enrichment = Δ Δ−2 Ct.
RNA aptamer-based affinity purification. To identify p32-CARF-XRN2 
binding sites on SAMMSON, the RAT-tag based method was used47 with slight 
modifications. Briefly, a mixture of three plasmids was co-transfected into 
HEK293T cells; one plasmid expressed RAT-tagged SAMMSON derivatives, one 
plasmid y18Sn tagged U2 (pcDdCMV-y18Sn-U249) for transfection control and 
one plasmid expressed HA-FLAG (HF)-tagged PP7CP (pcDNA3.1-PP7CP-HF) 
in a 7:2:1 ratio. The 24 h post-transfection medium was changed and after 4 h of 
incubation cells were collected. The cells were then lysed in lysis buffer (50 mM 
Tris-HCl pH 8.0, 150 mM NaCl, 2.5 mM MgCl2, 0.5% IGEPAL-CA630, 1 mM 
phenylmethylsulfonyl fluoride, PMSF) and incubated on ice for 15 min. The 
soluble fraction, obtained after centrifugation at 20,000 xg for 15 min at 4 °C, 
was mixed with anti-FLAG-M2-conjugated agarose beads and rotated for 4 h at 
4 °C. PP7CP-HF bound to RAT-tagged SAMMSON RNA–protein complexes was 
captured by the beads. After five washes with lysis buffer and once with lysis buffer 
without IGEPAL-CA630, RAT-tagged SAMMSON or its derivative bound with its 
associated proteins were eluted from the beads with 500 μ g ml−1 FLAG peptide in 
the same buffer.
RT–qPCR. RNA was extracted with QIAzol lysis reagent (Qiagen) or with 
Nucleospin RNA/protein kit (Macherey-Nagel). RNA was reverse transcribed 
using the High-Capacity complementary DNA Reverse Transcription Kit (Thermo 
Fisher Scientific). SAMMSON, TERRA, MALAT1, LINC00698, p32, COX1, 
ND1, 18S, 16S and 12S expression was measured by qPCR on a LightCycler 480 
(Roche) and normalized in qbase + 3.0 (Biogazelle) using HPRT1, TBP and UBC as 
reference genes. Sequences of the primers are indicated in Supplementary Table 1.
Northern blotting. Nuclear pre-rRNA-processing analysis was conducted as 
previously described50. For northern blot analysis of mitochondrial pre-rRNAs, 4 µ g  
of total RNA was subjected to 0.9% agarose-formaldehyde gel electrophoresis in 
3-(N-morpholino)propanesulfonic acid running buffer and the separated RNAs 
were transferred to a Hybond-N + membrane (GE Healthcare). The membrane 
was dried and subsequently crosslinked at 120 mJ cm−2. After being stained with 
methylene blue, the membrane was hybridized to biotin-labeled DNA probe at 
42 °C overnight in PerfectHyb Plus hybridization buffer (Sigma-Aldrich) according 
to the manufacturer’s instructions. The hybridized membrane was washed 
sequentially with 2× sodium lauryl sulfate containing 0.1% sodium dodecyl sulfate 
at 25 °C for 5 min, 0.5× sodium lauryl sulfate containing 0.1% sodium dodecyl 
sulfate at 50 °C for 20 min, and 0.1× sodium lauryl sulfate containing 0.1% sodium 
dodecyl sulfate at 25 °C for 20 min. The hybridized RNAs were detected using a 
Chemiluminescent Nucleic Acid Detection Module kit (Thermo Fisher Scientific) 
according to the manufacturer’s instructions. RNA signals were detected using 
LAS4000 image analyzer and the signal intensities of RNA bands were quantified 
by Image J software.
Library preparation, small RNA-seq and data processing. Small RNA libraries 
were generated using the TruSeq small RNA library prep kit (Illumina) on 100 ng 
of input RNA according to the manufacturer’s instructions. Size selection was 
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performed using a Pippin prep device (Sage Science). Libraries were quantified 
using a BioAnalyser (Agilent) and sequenced on a NextSeq500 (Illumina).
Small RNAs were quantified using Biogazelle’s dedicated small RNA-seq 
pipeline (part of Cobra). Adaptors were trimmed using Cutadapt, discarding reads 
shorter than 15 nt and reads without adaptors.
Read quality was evaluated using the FASTX-Toolkit, applying a minimum 
quality score of 20 in at least 80% of bases. Reads were mapped using Bowtie 
without allowing mismatches. Mapped reads were subsequently annotated by 
matching genomic coordinates of each read with genomic locations of miRNAs 
(obtained from miRBase, v2051) and other small RNAs (obtained from UCSC  
and Ensembl52,53).
SUNsET. SUNsET was performed as described35. Briefly, ~80% confluent  
cells were washed twice in 1× phosphate buffer saline and subsequently  
pulsed with puromycin-containing media (InvivoGen, 10 μ g ml−1) for 10 min. 
Due to the fact that puromycin is a structural analogue of aminoacyl tRNAs, it 
gets incorporated into the nascent polypeptide chain and prevents elongation. 
Thus, when used for reduced amounts of time, puromycin incorporation in 
neosynthesized proteins directly reflects the rate of mRNA translation in vitro. 
Puromycin incorporation was measured by western blotting using an antibody  
that recognizes puromycin.
Click-iT metabolic labeling for protein. Click-iT protein labeling  
(Invitrogen) was performed according to the manufacturer’s instruction.  
Cells were incubated for 1 h in methionine-free medium. Afterwards,  
50 µ M l-azidohomoalanine were added to the media for 3 h. The signal was 
detected using an horseradish peroxidase- (HRP)-conjugated streptavidin  
antibody (ab7403, Abcam, 1:20,000).
Cellular fractionation and mitoplast isolation. Briefly, mitochondria were 
purified from 4–6 × 107 cells using mitochondria isolation kit for cultured cells 
(Thermo Fisher Scientific) according to manufacturer instructions, all buffers were 
supplemented with 60 U ml−1 Superase-In (Ambion) and 1× Halt Protease and 
Phosphatase Inhibitor Single-Use Cocktail (Life Technologies)). Mitoplasts were 
obtained by incubating purified mitochondria in RNase A-containing hypotonic 
buffer (HEPES pH 7.2 supplemented with 1× Halt Protease and Phosphatase 
Inhibitor Single-Use Cocktail (Life Technologies) and 10 μ g ml−1 RNase A (Roche)) 
for 20 min on ice and subsequently incubated for an additional 10 min at room 
temperature to remove all possible RNA contaminants. The purified mitoplasts 
were then washed three times with Mitoplast Isolation Buffer (250 nM Mannitol, 
5 mM HEPES pH 7.2, 0.5 mM EGTA, 1 mg ml−1 bovine serum albumin (BSA) 
supplemented with 60 U ml−1 Superase-In (Ambion) and 1× Halt Protease and 
Phosphatase Inhibitor Single-Use Cocktail (Life Technologies)). For proteinase 
K experiments, purified mitochondria were resuspended in 1× sucrose buffer 
(HEPES 10 mM, sucrose 280 mM, EGTA 1 mM pH 7.4) supplemented with  
100 µ g ml−1 proteinase K (Sigma-Aldrich) and with 60 U ml−1 Superase-In 
(Ambion) for 30 min at 4 °C rotating. Mitochondria were then pelleted at 9,000g 
for 10 min. Afterwards, mitochondria were resuspended in 1× sucrose buffer 
supplemented with 20 nM PMSF (Sigma-Aldrich) and with 60 U ml−1 Superase-
In (Ambion) and pelleted at 9,000g for 10 min. An additional washing step was 
performed with 1× sucrose buffer supplemented with 20 nM PMSF (Sigma-
Aldrich) and 1× Halt Protease and Phosphatase Inhibitor Single-Use Cocktail  
(Life Technologies) and with 60 U ml−1 Superase-In (Ambion). RNA and protein 
were then extracted with Nucleospin RNA/protein kit (Macherey-Nagel). 
Mitochondria and mitoplast enrichment was validated by RT–qPCR for the 
16S mt-rRNA and by western blot using antibodies directed against multiple 
mitochondrial proteins and calreticulin or calnexin (to exclude the possibility of 
endoplasmic reticulum contaminants). The same amount of proteins was loaded 
on the gel for each fraction to compare the enrichment of the different fractions.
Antibodies. Western blotting experiments were performed using the following 
primary antibodies: vinculin (V9131, clone hVIN-1 Sigma-Aldrich, 1:10,000), 
GAPDH (ab9485, Abcam, 1:1,000 or AM4300, clone 6C5, Ambion, 1:20,000), 
β-actin (sc-69879, clone AC-15, Santa Cruz Biotechnology, 1:2,000), p32 
(A302-863A, Bethyl Laboratories, 1:5,000 or sc-10258, clone D-19, Santa Cruz 
Biotechnology, 1:1,000), XRN2 (A301-103A, Bethyl Laboratories, 1;2,000), CARF 
(A303-861A, Bethyl Laboratories, 1:2,000), NDUFS3 (Abcam 14711, 1:1,000), 
VDAC1 (ab3434-100, Abcam, 1:2,000), Hsp60 (BD611562, BD Biosciences, 
1:5,000), Tom20 (FL-145, sc-11415, Santa Cruz Biotechnology, 1:1,000), 
calreticulin (C4606, Sigma-Aldrich, 1:10,000), calnexin (ab22595, Abcam,  
1:5,000), SRSF1 (32-4600, Thermo Fisher Scientific, 1:250), puromycin (MABE343, 
clone 12D10, Merck Millipore, 1:25,000) and HA-tag (3724, clone C29F4, Cell 
Signaling Technologies, 1:1,000). The following HRP-linked secondary antibodies 
were used: anti-goat IgG (A5420, Sigma-Aldrich, 1:10,000), anti-mouse IgG 
(7076S, Cell Signaling Technologies, 1:5,000) and anti-rabbit IgG (NA934-1ML, 
Sigma-Aldrich, 1:10,000).
Fluorescence in situ hybridization (FISH). For detection of NEAT1 and the 12S 
at a single-cell level, pools of FISH probes were designed using the Stellaris probe 
designer software (Biosearch Technologies). Cells were grown on eight-well slides 
and fixed in 3.7% formahldeyde and permeabilized in 70% EtOH for > 15 min at 
4 °C. Hybridization was carried out overnight at 37 °C in 2× sodium lauryl sulfate, 
10% formamide and 10% dextran. Cells were counterstained with 4,6-diamidino-
2-phenylindole (DAPI) and visualized using an Olimpus Fluoview FV1200 using a 
LD635 laser for Cy5, LD559 HeNe for Cy3.5 and LD405 for DAPI.
Immunofluorescence. For immunofluorescence, cells were grown on eight-well 
slides, fixed in 3.7% formahldeyde and permeabilized in 1% BSA (Sigma-Aldrich) 
and 0.2% Triton X-100 (Sigma-Aldrich)-containing buffer for 10 min on ice. 
Blocking was performed in 1% BSA and 10% goat serum (DAKO) for 30 min 
at room temperature. Primary antibody incubation was performed at room 
temperature for 1 h. To detect p32, a rabbit antibody (A302-863A) from Bethyl 
Laboratories was used at a concentration of 1:1,000. To detect XRN2, a rabbit 
antibody (A301-103A) from Bethyl Laboratories was used at a concentration 
of 1:250. To detect CARF, a mouse antibody (H00055602-B01P) from Abnova 
was used at a concentration of 1:200. To detect puromycin, a mouse antibody 
(MABE343, clone 12D10) from Merck Millipore was used at a concentration  
of 1:10,000. To detect fibrillarin, a mouse antibody (ABIN361375, clone 38F3)  
from Anticorps was used at a concentration of 1:500. Secondary antibody 
incubation was performed for 45 min at room temperature in the dark. 
As secondary antibodies, anti-rabbit or anti-mouse AlexaFluor-488 and 
AlexaFluor-647 (Life Technologies, 1:1,000) were used. MitoTracker™ Red 
CMXRos (Thermo Fisher Scientific) was added to the cells at a final concentration 
of 300 nM 30 min prior to fixation. Slides were then mounted with ProLong Gold 
Antifade Mountant with DAPI (Thermo Fisher Scientific). Images where analyzed 
on an Olympus Fluoview FW1200 using a LD635 laser for Cy5, LD559 HeNe for 
Cy3.5 and LD405 for DAPI.
Proximity ligation assay (PLA). PLA Duolink FarRed (Sigma-Aldrich) was 
performed following the manufacturer’s instructions. To detect p32, a rabbit 
antibody (A302-863A) from Bethyl Laboratories was used at a concentration of 
1:1,000. To detect CARF, a mouse antibody (H00055602-B01P) from Abnova was 
used at a concentration of 1:200. PLA Probe Anti-Rabbit PLUS and PLA Probe 
Anti-Mouse MINUS were used.
Xenografts. Animals were housed under pathogen-free conditions. All procedures 
involving animals (NMRI, female, 4 weeks old) were performed in accordance 
with the guidelines of the Catholic University of Leuven (KU Leuven) Animal 
Care and Use Ethical Committee (P147/2012). At the age of 4 weeks, mice were 
injected subcutaneously in either one or both flanks with 5 × 106 Mel-ST cells 
in 100 µ l serum-free medium. Tumor volumes were calculated with the formula 
L × W × H × 0.52, where L is length, W is width and H is height.
Immunohistochemistry. Tumor samples were fixed in 3.7% PFA for 24 h at 
4 °C, dehydrated with 70% EtOH for 24 h at 4 °C and subsequently rehydrated 
with demineralized water. The samples were then cut in sections of about 4 μ m. 
Specimens were stained with haematoxylin and eosin and immunohistochemistry 
was performed using microwave pre-treatment of slides for antigen retrieval. 
Antibodies against Ki-67 (SP6, Thermo Fisher Scientific RM-9106-S, clone SP6, 
1:200) and puromycin (Merck Millipore, clone 12D10, 1:15,000) were applied, 
in conjunction with goat anti-rabbit HRP-conjugated antibodies (DAKO) and 
visualized by DAB reaction. To evaluate the stainings, positive cells were counted 
using ImageJ.
RNA–protein interactions (catRAPID). Interactions of SAMMSON to XRN2, 
CARF and p32 were predicted using catRAPID54,55, an algorithm that computes 
RNA–protein interactions by combining secondary structure, hydrogen bonding 
and van der Waals contributions. Background correction was obtained by 
subtracting the profile of AQP1, a bona fide negative control, not retrieved in the 
mass spectrometry data from SAMMSON pulldown.
Statistical analysis. The significance between means was determined by two-
tailed paired Student′ s t-test, with the exception of Fig. 6b where two-way analysis 
of variation (ANOVA) was used and of Supplementary Fig. 8c where a two-
tailed unpaired Student′ s t-test was used. P values are represented as P > 0.05, 
not significant (NS); P < 0.05, *; P < 0.01, **; P < 0.001, ***; P < 0.0001, ****. All 
statistical analyses were performed with GraphPad Prism v7.0a (April 2, 2016)  
for Mac OS X.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
Small RNA sequencing data have been submitted to the Sequence Read Archive 
under accession code SRP151840. Source data and statistical analysis for  
Figs. 1a,b,d,e, 2a,c,e,f, 3a,d,f,h, 4c,e, 5c, 6d,g,h and 7b–g are available in the in the 
Supplementary Information online. All other data that support the findings of this 
study are available from the corresponding author upon reasonable request.
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Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life 
science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list 
items might not apply to an individual manuscript, but all fields must be completed for clarity. 
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research 
policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Please do not complete any field with "not applicable" or n/a.  Refer to the help text for what text to use if an item is not relevant to your study. 
For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.
?    Experimental design
1.   Sample size
Describe how sample size was determined. Sample size was determined empirically. No statistical methods were used to predetermine 
sample size. 
For animal experiments, a pilot study was run to assess the tumor-forming capacity and the 
latency of the cells at three different cell concentrations. Based on those results (100% of 
tumor growth regardless of the concentration), n=8 was chosen to assess whether an effect 
was present.
2.   Data exclusions
Describe any data exclusions. No data were excluded from the analyses.
3.   Replication
Describe the measures taken to verify the reproducibility 
of the experimental findings.
All experiments were performed at least in three independent biological replicates. Reagents 
were freshly prepared for every experiment and different batches of reagents were used for 
separate biological replicates. Some experiments were independently run by two different 
people to corroborate the findings. The number of replicates is indicated for each 
experiment.
4.   Randomization
Describe how samples/organisms/participants were 
allocated into experimental groups.
For cell lines undergoing a treatment, cells were plated from the same aliquot at the same 
density and subsequently treated accordingly.  
For lentiviral infection, cells were infected at the same time with empty or GOI-encoding 
plasmid with virus with the same m.o.i. produced on the same day. Only cells infected at the 
same time were used for each experiment. For biological replicates, cells infected with 
different batches of virus were used.  
For mice experiments, mice were injected with cells infected with an empty construct on one 
flank and with the GOI-carrying construct on the other flank.
5.   Blinding
Describe whether the investigators were blinded to 
group allocation during data collection and/or analysis.
Form mouse studies, no blinding was needed since both conditions were injected in the same 
mouse. To document the findings, pictures of each tumor (containing a unit of measure) 
were taken.
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
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6.   Statistical parameters 
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the 
Methods section if additional space is needed). 
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same 
sample was measured repeatedly
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
Test values indicating whether an effect is present 
Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
?   Software
Policy information about availability of computer code
7. Software
Describe the software used to analyze the data in this 
study. 
All analyses were performed with GraphPad Prism v7.0a (April 2, 2016) for Mac OS X.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made 
available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for 
providing algorithms and software for publication provides further information on this topic.
?   Materials and reagents
Policy information about availability of materials
8.   Materials availability
Indicate whether there are restrictions on availability of 
unique materials or if these materials are only available 
for distribution by a third party.
All materials and reagents are available from standard commercial sources. 
DNA constructs are available from the authors upon reasonable requests.
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9.   Antibodies
Describe the antibodies used and how they were validated 
for use in the system under study (i.e. assay and species).
The following primary antibodies were used: vinculin (V9131, clone hVIN-1, Sigma-Aldrich, 
LOT#129K484P), GAPDH (ab9485, Abcam, LOT#GR301708-1 and 6C5, AM4300, Ambion, 
LOT#00326548), b-actin (AC-15, sc-69879, Santa Cruz Biotechnology, LOT#K1715), p32 
(A302-863A, Bethyl Laboratories, no LOT# provided; A302-862A, Bethyl Laboratories, no 
LOT# provided and D-19, sc-10258, Santa Cruz Biotechnology, LOT#D3004), XRN2 
(A301-103A, Bethyl Laboratories, no LOT# provided), CARF (A303-861A, Bethyl Laboratories, 
no LOT# provided; A303-862A, Bethyl Laboratories, no LOT# provided; H00055602-B01P, 
Abnova, LOT#10252), NDUFS3 (Abcam 14711, LOT#GR192954-4), VDAC1 (ab3434-100, 
Abcam, LOT#GR103383-1), Hsp60 (BD611562, BD Biosciences, LOT# not available), Tom20 
(sc-11415, Santa Cruz Biotechnology, LOT# not available), calreticulin (C4606, Sigma-Aldrich), 
calnexin (ab22595, Abcam, LOT# not available), puromycin (MABE343, clone 12D10, Merck-
Millipore, LOT#2672968), SRSF1 (32-4600, Thermo Fisher Scientific, LOT#RFC34850), HA-tag 
(3724, clone C29F4, Cell Signaling Technologies, LOT#7, REF 09/2015), fibrillarin, 
(ABIN361375, clone 38F3, Anticorps, LOT#GS1114b), Ki-67 (SP6, Thermo Fisher Scientific 
#RM-9106-S, clone SP6, LOT#9106RQ1509B). The following HRP-linked secondary antibodies 
were used: anti-goat IgG (A5420, Sigma-Aldrich, LOT# not available), anti-mouse IgG (7076S, 
Cell Signaling Technologies, LOT#32 03/2016), anti-rabbit IgG (NA934-1ML, Sigma-Aldrich, 
LOT#16803301). The following fluorescent goat cross-adsorbed secondary antibodies were 
used: anti-mouse Alexa Fluor 488 (A11001, Thermo Fisher Scientific, LOT#17525114), anti-
mouse Alexa Fluor 647 (A21235, Thermo Fisher Scientific, LOT#1786359), anti-rabbit Alexa 
Fluor 488 (A11008, Thermo Fisher Scientific, LOT#1885240), anti-rabbit Alexa Fluor 647 
(A21246, Thermo Fisher Scientific, LOT#1596041). 
The dilutions of the different antibodies were described in the Materials & Methods section. 
Information regarding validation, citations, and antibody profiles are available on the 
manufacturer's website. XRN2, p32 and CARF antibodies were further validated by KD with 
siRNAs followed by western blotting and IF. VDAC1, NDUFS3, Hsp60, Tom20, vinculin, GAPDH, 
calreticulin and calnexin were validated by cellular fractionation followed by western blotting. 
Fibrillarin was validated by immunofluorescence. HA-tag was validated by using positive and 
negatives controls. Puromycin was validated both in vitro and in vivo by western blotting, 
immunofluorescence and ICH using positive and negatives controls.
10. Eukaryotic cell lines
a.  State the source of each eukaryotic cell line used. SK-MEL-28, provider: Lionel Larue. 
SK-MEL-28 BRAFi resistant, provider: Daniel Peeper. 
Raji, provider: Lorenzo Leoncini. 
LCLs, provider: Lorenzo Leoncini. 
Mel-ST, provider: Corine Bertolotto. 
HEK293T, provider: ATCC. 
p38, provider: ATCC. 
MM cell lines, provider: Ghanem-Elias Ghanem. 
NHEM, provider: KU Leuven Dpt. Human Genetics.
b.  Describe the method of cell line authentication used. All cell lines were routinely tested by RT-qPCR and wester blot using cell type-specific 
markers.
c.  Report whether the cell lines were tested for 
mycoplasma contamination.
All cell lines were frequently tested for mycoplasma contamination and were always found 
negative.
d.  If any of the cell lines used are listed in the database 
of commonly misidentified cell lines maintained by 
ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
?    Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
11. Description of research animals
Provide all relevant details on animals and/or 
animal-derived materials used in the study.
Species: Mus Musculus. 
Strain: NMRI nude mice (BomTac:NMRI-Foxn1nu). 
Sex: females. 
Age: 4 weeks (start of the experiment)-12 weeks (end of the experiment).
Policy information about studies involving human research participants
12. Description of human research participants
Describe the covariate-relevant population 
characteristics of the human research participants.
This study did not involve human participants.
